Secretome Therapeutics to present STM-01 Phase 1 HFpEF data at HFSA
Secretome Therapeutics said clinical data from its Phase 1 study of STM-01 in heart failure with preserved ejection fraction will be presented at the HFSA Annual Scientific Meeting.
Secretome Therapeutics said clinical data from its Phase 1 study of STM-01 in heart failure with preserved ejection fraction will be presented at the HFSA Annual Scientific Meeting.